Is there a role for immunotherapy in HER2-positive breast cancer?

Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable d...

Descripción completa

Detalles Bibliográficos
Autores principales: Holgado, Esther, Perez-Garcia, Jose, Gion, Maria, Cortes, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093898/
https://www.ncbi.nlm.nih.gov/pubmed/30131972
http://dx.doi.org/10.1038/s41523-018-0072-8
_version_ 1783347741480452096
author Holgado, Esther
Perez-Garcia, Jose
Gion, Maria
Cortes, Javier
author_facet Holgado, Esther
Perez-Garcia, Jose
Gion, Maria
Cortes, Javier
author_sort Holgado, Esther
collection PubMed
description Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable disease. Thus, new and better therapeutic options are urgently needed. Among them, are the agents stemming from the field of immunology that have been the focus of impressive scientific progress and new therapeutic opportunities seem to emerge “every day” in a variety of tumor types.
format Online
Article
Text
id pubmed-6093898
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60938982018-08-21 Is there a role for immunotherapy in HER2-positive breast cancer? Holgado, Esther Perez-Garcia, Jose Gion, Maria Cortes, Javier NPJ Breast Cancer Perspective Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable disease. Thus, new and better therapeutic options are urgently needed. Among them, are the agents stemming from the field of immunology that have been the focus of impressive scientific progress and new therapeutic opportunities seem to emerge “every day” in a variety of tumor types. Nature Publishing Group UK 2018-08-15 /pmc/articles/PMC6093898/ /pubmed/30131972 http://dx.doi.org/10.1038/s41523-018-0072-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Holgado, Esther
Perez-Garcia, Jose
Gion, Maria
Cortes, Javier
Is there a role for immunotherapy in HER2-positive breast cancer?
title Is there a role for immunotherapy in HER2-positive breast cancer?
title_full Is there a role for immunotherapy in HER2-positive breast cancer?
title_fullStr Is there a role for immunotherapy in HER2-positive breast cancer?
title_full_unstemmed Is there a role for immunotherapy in HER2-positive breast cancer?
title_short Is there a role for immunotherapy in HER2-positive breast cancer?
title_sort is there a role for immunotherapy in her2-positive breast cancer?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093898/
https://www.ncbi.nlm.nih.gov/pubmed/30131972
http://dx.doi.org/10.1038/s41523-018-0072-8
work_keys_str_mv AT holgadoesther istherearoleforimmunotherapyinher2positivebreastcancer
AT perezgarciajose istherearoleforimmunotherapyinher2positivebreastcancer
AT gionmaria istherearoleforimmunotherapyinher2positivebreastcancer
AT cortesjavier istherearoleforimmunotherapyinher2positivebreastcancer

Ejemplares similares